Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.

Donato Rigante, Raffaele Manna, J Sota, A Insalaco, P Sfriso, Vita S de, R Cimaz, G Lopalco, G Emmi, Torre F La, C Fabiani, AN Olivieri, M Cattalini, D Cammelli, R Gallizzi, M Alessio, O Viapiana, M Frassi, A Maier, C SalvaraniR Talarico, R Priori, MC Maggio, M Pardeo, C Gaggiano, S Grosso, Benedetti F De, A Vitale, L Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

We have evaluated anakinra drug retention rate and predictive factors of drug survival in a cohort of patients with systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). Our findings show an overall excellent drug retention rate of anakinra on the long run for both sJIA and AOSD that may be further optimized by closely monitoring patient’s safety issues and employing this interleukin-1 inhibitor as a first-line biologic drug as early as possible. Moreover, the use of anakinra allowed a significant other drug-sparing effect while showing a good safety profile.
Lingua originaleEnglish
pagine (da-a)1-2
Numero di pagine2
RivistaPEDIATRIC RHEUMATOLOGY ONLINE JOURNAL
Volume10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Stato di pubblicazionePubblicato - 2019

Keywords

  • Anakinra

Fingerprint

Entra nei temi di ricerca di 'Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.'. Insieme formano una fingerprint unica.

Cita questo